Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges
May 14, 2026DOI: 10.1056/nejmc2604136CorrespondenceNEJM
To the Editor: Recently, Rana et al. published the results of the LATITUDE trial, which involved a population of patients with challenges in adhering to antiretroviral treatment. The results are very encouraging for the future of injectable treatment in this population. The authors state that standard care was a regimen of three or more drugs that included an integrase strand-transfer inhibitor (INSTI), protease inhibitor, or both; however, given that efficacy and side effects differ among regimens, it would be interesting to know which specific antiretroviral regimens served as the comparator for the injectable treatment. Furthermore, 120 patients were excluded from . . .